€1.46
Your prediction
Aldeyra Therapeutics Inc. Stock
Pros and Cons of Aldeyra Therapeutics Inc. in the next few years
Pros
Cons
Performance of Aldeyra Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics Inc. | -0.670% | -8.750% | -0.680% | -37.872% | -66.968% | -85.853% | - |
| Heron Therapeutics Inc. | 5.540% | -7.752% | -65.640% | -80.843% | -68.169% | -69.431% | -97.164% |
| Evolus Inc | -0.690% | 9.624% | 5.568% | -33.529% | 3.670% | -26.144% | -36.872% |
| Rhythm Pharmaceuticals | -0.680% | 2.740% | -6.250% | 30.435% | -19.786% | 368.750% | 390.196% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.General Impressions on Financials
A cursory glance at the financials of the Biotechnology & Medical Research industry stalwart, Aldeyra, reveals a mixed bag. The balance sheets show an upward trend in their total assets over the years. From 83 million in 2020, their total assets rose exponentially to 233 million in 2021, tapering off slightly to 181 million in 2022. Although declining in the recent year, the overall upward trajectory in assets reflects a positive signal, indicative of the company's ability to increase its asset base.
However, delving into the financial health of Aldeyra offers a contrasting picture. The company's net income has consistently been in the negative over the past three years, indicating that the company is not turning a profit. The EBIT value is persistently negative as well, implying that the firm is facing operational challenges and struggling to control its operating costs. Moreover, the company seems to heavily rely on external funding to finance its growth as suggested by its negative net debt, which points to the fact that the company has more cash than debt on its books.
Comments
News
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Key Points
- Interested in Aldeyra Therapeutics, Inc.? Here are five stocks we like better.
- Aldeyra Therapeutics is awaiting near-term FDA feedback on its dry eye drug reproxalap after a third
